This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/resource/domain/vavai/subjekt/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064211%3A_____%2F12%3A%230000124%21RIV13-MZ0-00064211/
n13http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064211%3A_____%2F12%3A%230000124%21RIV13-MZ0-00064211
rdf:type
skos:Concept n17:Vysledek
rdfs:seeAlso
http://link.springer.com/article/10.1007%2Fs00280-011-1772-z
dcterms:description
A drug?drug interaction was seen in this trial with bexarotene co-administration leading to a significant reduction in the AUC of atorvastatin. The likely mechanism for this interaction is through induction of CYP3A4 by bexarotene given the role of this enzyme in the metabolism of atorvastatin. Knowledge of this interaction is important for optimizing lipid management with atorvastatin for patients receiving bexarotene. A drug?drug interaction was seen in this trial with bexarotene co-administration leading to a significant reduction in the AUC of atorvastatin. The likely mechanism for this interaction is through induction of CYP3A4 by bexarotene given the role of this enzyme in the metabolism of atorvastatin. Knowledge of this interaction is important for optimizing lipid management with atorvastatin for patients receiving bexarotene.
dcterms:title
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
skos:prefLabel
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
skos:notation
RIV/00064211:_____/12:#0000124!RIV13-MZ0-00064211
n17:predkladatel
n19:ico%3A00064211
n4:aktivita
n15:I n15:N
n4:aktivity
I, N
n4:cisloPeriodika
2
n4:dodaniDat
n9:2013
n4:domaciTvurceVysledku
n12:7693028
n4:druhVysledku
n18:J
n4:duvernostUdaju
n6:S
n4:entitaPredkladatele
n16:predkladatel
n4:idSjednocenehoVysledku
132939
n4:idVysledku
RIV/00064211:_____/12:#0000124
n4:jazykVysledku
n11:eng
n4:klicovaSlova
Bexarotene; Atorvastatin; Pharmacokinetics; Non-small cell lung cancer
n4:klicoveSlovo
n7:Pharmacokinetics n7:Atorvastatin n7:Bexarotene n7:Non-small%20cell%20lung%20cancer
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[22E4D4AC3F60]
n4:nazevZdroje
Cancer Chemotherapy and Pharmacology
n4:obor
n5:FC
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
13
n4:rokUplatneniVysledku
n9:2012
n4:svazekPeriodika
69
n4:tvurceVysledku
Hao, D. Lopez-Anaya, A. Rodon, J. Takimoto, CH. H. Chu, Q. Rowinsky, E. K. Middleton, G. Wakelle, H. A. Dunlop, D. Leighl, N. Zatloukal, Petr Jacobs, C. D. Ramlau, R.
n4:wos
000299516700030
s:issn
0344-5704
s:numberOfPages
8
n13:doi
10.1007/s00280-011-1772-z